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In selected patients with an acute myocardial infarction (AMI) complicated by Cardiogenic
shock (CS), mechanical circulatory support with Impella may be beneficial, although conclu-
sive evidence is still lacking. Nevertheless, it has been suggested that Impella initiation prior
to primary PCI might improve survival.
Objective
To investigate the effect pre-PCI versus immediate post-PCI Impella initiation on short term
mortality.
Methods
A prospective, single center, observational study, was performed including all patients with
STEMI complicated by CS, treated with primary PCI and Impella. Thirty day mortality was
compared between patients with Impella initiation pre-PCI and immediately post-PCI.
Results
A total of 88 patients were included. In the pre-PCI group (n = 21), admission heart rate was
lower (84 versus 94 bpm, p = 0.04) and no IABP was implanted before Impella initiation, ver-
sus 17.9% in post-PCI group (n = 67), p = 0.04. Total 30-day all-cause mortality was 58%,
and was lower in pre-PCI group, 47.6% versus 61.2% in the post-PCI group, however not
statistically significant (HR 0.7, 95% CI 0.3–1.3, p = 0.21). Thirty-day cardiac mortality was
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significantly lower in the pre-PCI group, 19% versus 44.7% in the post-PCI group (HR 0.3,
95% CI 0.09–0.96, p = 0.042).
Conclusion
Pre-PCI Impella initiation in AMICS patients was not associated with a statistically significant
difference in 30-day all-cause mortality, compared to post-PCI Impella initiation.
Introduction
Cardiogenic shock (CS) occurs in 5–10% of patients with acute myocardial infarction (AMI)
and is still associated with 30-day mortality of approximately 40–60% despite emergent revas-
cularization of the culprit lesion [1–4]. Medical treatment with inotropes and vasopressors do
not improve survival. Current European and American guidelines give a class IIb recommen-
dation for short-term mechanical circulatory support (MCS) in patients with refractory shock
[5, 6]. However, routine MCS with an Intra-aortic balloon pump (IABP) initiated either before
or after primary percutaneous coronary intervention (PCI) does not reduce mortality [7, 8].
Given the persistently high mortality in patients with AMI complicated by CS (AMICS), there
is an urgent need to improve treatment in these patients. The use percutaneous MCS devices
that provide more hemodynamic support than an IABP, such as an Impella, might be a possi-
ble beneficial strategy [9].
The Impella (Abiomed, Danvers, MA), is a catheter-based microaxial flow pump placed
across the aortic valve into the left ventricle (LV). It unloads the LV and increases the cardiac
output and coronary blood flow [10, 11]. It also increases the Cardiac Power Output, which
has previously been shown to be the strongest hemodynamic predictor of mortality in AMICS
patients [12, 13]. The Impella devices for LV-support, consist of the Impella 2.5, CP and 5.0.
The Impella 2.5 and CP can be inserted percutaneously and provide a maximum output of
respectively 2.5 L/min and 3.7 L/minute, whereas the Impella 5.0 needs to be inserted surgi-
cally and generates a maximum output of 5 L/min. Despite increased hemodynamic support
with Impella, compared to IABP, there is conflicting evidence regarding the effect of Impella
on clinical outcome [14–19]. However, in the studies with neutral or negative effect of Impella,
most patients received Impella after primary PCI, while it has been suggested that Impella ini-
tiation prior to primary PCI might be a better strategy to improve survival than Impella initia-
tion after primary PCI [20–22]. Unfortunately, previous studies assessing early Impella
initiation in AMICS patients had major limitations, including a long or unclear period
between Impella initiation and primary PCI and a small sample size.
Therefore, it remains unknown whether early Impella initiation may improve survival in
AMICS patients as compared to delayed initiation. We investigated the effect of Impella initia-
tion immediately before versus immediately after primary PCI on 30-day mortality in a large
prospective cohort of AMICS patients.
Methods
Patient population
Data for this study are from the prospective cohort of patients who received an Impella at the
Amsterdam University Medical Center (AUMC), The Netherlands. Our center is a high vol-
ume tertiary referral hospital with on-site cardiac surgery. All patient hospitalized between
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June 2006 and December 2016 with STEMI complicated by CS, treated with primary PCI and
MCS with percutaneous Impella 2.5 or CP or surgical Impella 5.0 (Abiomed Inc., Massachu-
setts), were included in this study. Patients who did not receive Impella support in the same
session as the primary PCI procedure, were excluded in order to avoid bias from delayed
Impella therapy.
The Amsterdam University Medical Center Institutional Review Board approved the study
and waived the requirement for informed consent in accordance with the Declaration of Hel-
sinki. All data were fully anonymized.
Treatment
All AMICS patients were treated with primary PCI according to standard PCI protocol. Before
primary PCI, all patients received intravenous aspirin (500mg) loading dose, a P2Y12 blocker
(either 600 mg of Clopidogrel or 180 mg of Ticagrelor) loading dose orally or via an esophageal
tube when intubated and intravenous unfractionated heparin (5000 IU). Adjunctive treatment
with glycoprotein IIb/IIIa inhibitors was at the discretion of the treating interventional cardiol-
ogist. Also the timing of Impella support (before or immediately after primary PCI) was left at
the discretion of the treating interventional cardiologist. Post-PCI all patients received lifelong
aspirin 100mg once daily and a P2Y12 blocker for 12 months (either 75 mg of Clopidogrel
once daily or 180 mg of Ticagrelor twice daily).
Before 2012, only the Impella 2.5 and Impella 5.0 were available. After its introduction in
2012, the Impella CP became the first choice device in AMICS patients. Impella performance
was set to a maximum level without console alarms (suction or position). Duration of Impella
support was at discretion of the treating physicians. Upgrade to an Impella device with more
hemodynamic support was considered when the device used was deemed to provide insuffi-
cient support. This was the case in patients who exhibited a combination of worsening hemo-
dynamics and/or increased need for inotropes and vasopressors despite high Impella
performance, together with an overall assessment of the patient and his/her neurological sta-
tus. During Impella support, all patients were treated with unfractionated heparin in order to
maintain an activated partial thromboplastin time (APTT) between 45 and 60 seconds.
Weaning was not formally protocolized but was evaluated daily by the treating physician
and typically started on signs of hemodynamic recovery, usually 12–24 hours after PCI, when
inotropes and vasopressors were reduced. Weaning usually occurred in two steps: from maxi-
mum possible support (P7–8) to approximately half support (P4–5) (if necessary patients were
observed for several hours, typically overnight), to low-level Impella support (P2–3) before
device removal. Device removal was typically also two-staged. First the device was pulled back
from the left ventricle into the descending aorta. The device was not switched off, but set to
level P1 in order to prevent thrombus formation. After 45–60 minutes of heparin cessation
depending of last activated clotting time (ACT) level, the device was removed, followed by
approximately 30 minutes of femoral compression.
Definitions
CS was defined as a systolic blood pressure� 90 mmHg for at least 30 minutes or the need for
vasopressors to maintain a systolic blood pressure > 90 mmHg, clinical signs of pulmonary
congestion and end-organ hypoperfusion (cool extremities, altered mental status, or a urine
output of<30 ml/hour [4]. Patients who received Impella support immediately before initia-
tion of the primary PCI (wiring of the infarct related artery), were defined as the pre-PCI
group. Patients who received Impella support during or immediately after initiation of the pri-
mary PCI in the same procedure, were defined as the post-PCI group. Thirty day all-cause
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mortality was defined as mortality within the hospital admission or up to 30-days after the pri-
mary PCI (index procedure), whichever was longer. Cardiac mortality was defined as mortality
due to refractory cardiogenic shock. Neurological mortality was defined as mortality due to
irreversible post-anoxic brain injury leading to persisting coma, judged by a consulting neurol-
ogist and a concurring computed tomography scan.
Analysis
Normally distributed continuous variables were reported as mean ± standard deviation (SD)
and compared with ANOVA corrected for multiple testing by Bonferroni. Skewed distributed
variables are presented as median and compared with the Wilcoxon rank sum test. Categorical
variables are presented as proportions and compared with Chi-square test.
Age was dichotomized above and below the age of 75 years. Creatinine was dichotomized
with the use of the clinical threshold for impaired renal function (>95 μmol/L for women and
>110 for men). Hemoglobin was dichotomized using the clinical threshold for anemia (7.5
mmol/L for women and 8.5 mmol/L for man). Arterial pH, lactate, glucose and peak creatine-
kinase (CK) MB were dichotomized according to the median value. Blood pressure at the time
of Impella placement was dichotomized using the clinical threshold of 90 mmHg for systolic
blood pressure and mean arterial pressure (MAP) of 60 mmHg. Cardiac arrest was categorized
in: no cardiac arrest, return-off-spontaneous circulation (ROSC) time below 20 minutes and
above 20 minutes.
Kaplan Meier analyses were calculated and a log-rank test was used to compare the clinical
outcomes between groups.
A Cox proportional-hazards regression model was used to calculate both uni-variable and
multi-variable adjusted hazard ratios, with calculation of 95% confidence intervals. Not all uni-
variate significant variables were added to the model because of the limited number of patients
and consequent loss of power of the model. A covariate was removed from the model if its sig-
nificance level exceeded p = 0.10. Variables included in the multivariable analysis were age,
sex, admission heart rate and IABP placement before Impella initiation. Analyses were per-
formed with SPSS (version 26.0, Chicago, Illinois).
Results
Patient population
A total of 88 patients were included in this study, with 21 patients (23.9%) in the pre-PCI and
67 patients (76.1%) in the post-PCI group. Baseline characteristics are summarized in Table 1.
Patients were 60 ± 10 years old and 82% was male. A total of 82% of patients suffered an ante-
rior located myocardial infarction, 69% had multivessel disease and 60% experienced cardiac
arrest before Impella initiation. Angiographic success was achieved in 76% of the patients. The
majority of patients were treated with catecholamines and/or inotropes and were mechanically
ventilated.
Patients in the pre-PCI group had a lower heart rate at admission (84 bpm versus 94 bpm,
p = 0.04). IABP prior to Impella initiation was statistically different between the pre-PCI and
post-PCI group, respectively 0 versus 12 patients (0% versus 17.9%, p = 0.04). Six patients in
the post-PCI group received IABP prior to primary PCI and prior to Impella initiation and 6
patients received IABP after primary PCI but prior to Impella initiation. Other baseline char-
acteristics were not statistically different.
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Table 1. Baseline characteristics of AMICS patients treated with primary PCI and Impella.
Pre-PCI Post-PCI
(n = 21) (n = 67) p
Clinical characteristics and risk factors
Age (years) 60.0 ± 11.7 61.2 ± 10.0 0.63
Male sex, n (%) 18 (85.7) 54 (80.6) 0.75
Body mass index (kg/m2) 25.7 [23.6–27.4] 26.0 [24.5–27.6] 0.69
Cardiovascular risk factors, n (%)
Current smoking 8 (40.0) 23 (44.2) 0.79
Hypertension 8 (40.0) 23 (35.9) 0.79
Diabetes mellitus 5 (25.0) 9 (13.4) 0.29
Prior myocardial infarction, n (%) 3 (16.7) 13 (19.7) 1.00
Prior TIA or stroke, n (%) 1 (5.0) 1 (1.5) 0.41
Known peripheral arterial disease, n (%) 1 (5.6) 4 (6.3) 1.00
Prior PCI or CABG, n (%) 5 (23.8) 10 (15.4) 0.50
Clinical characteristics on admission to the cardiac catheterization laboratory
Blood pressure values
Mean arterial pressure 59 [48–66] 67 [56–77] 0.51
Systolic blood pressure (mmHg) 80 [67–95] 86 [71–101] 0.55
Diastolic blood pressure (mmHg) 49 [40–58] 58 [45–67] 0.31
Heart rate (beats per minute) 84 [61–108] 94 [80–112] 0.04
Catecholamines or inotropes, n (%) 19 (90.5) 59 (88.1) 1.00
Mechanical ventilation, n (%) 18 (85.7) 60 (89.6) 0.69
Cardiac arrest, n (%) 11 (52.4) 42 (62.7) 0.62
Out of hospital cardiac arrest, n (%) 10 (47.6) 29 (43.2) 0.17
Witnessed arrest, n (%) 10 (47.6) 36 (53.7) 0.29
First rhythm VT/VF/AED, n (%) 8 (38.1) 35 (52.2) 0.23
Time till return of spontaneous circulation (min) 25 [18–50] 20 [11–53] 0.88
Traumatic injuries at admission, n/n (%) 2 (9.5) 4 (6.0) 0.62
Laboratory values on admission
Lactate (mmol/L) 7.7 [4.2–9.6] 6.5 [3.8–10.4] 0.94
Hemoglobin (mmol/L) 8.4 [7.4–9.0] 8.7 [7.6–9.4] 0.37
Creatinine (umol/l) 111 [98–133] 112 [89–128] 0.59
Glucose (mmol/L) 13.8 [11.0–18.0] 15.7 [11.1–20.4] 0.67
Arterial pH 7.22 [6.94–7.34] 7.18 [7.05–7.28] 0.70
Primary percutaneous coronary intervention
Ischemic time (min) 198 [118–414] 150 [96–219] 0.14
Infarct-related artery, n (%) 0.29
Left main 7 (33.3) 18 (26.9)
Left anterior descending 10 (47.6) 37 (55.2)
Left circumflex 1 (4.8) 9 (13.4)
Right coronary artery 3 (14.3) 3 (4.5)
Multi-vessel disease, n (%) 17 (81.0) 44 (65.7) 0.27
TIMI flow pre-PCI, n (%) 0.51
0 13 (61.9) 52 (77.6)
1 2 (9.5) 3 (4.5)
2 2 (9.5) 5 (7.5)
3 4 (19.0) 7 (10.4)
TIMI flow post-PCI, n (%) 0.38
(Continued)
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Clinical course
Characteristics of the clinical course are summarized in Table 2. The initial Impella strategy
consisted of Impella 2.5 in 35 patients (39.8%), Impella CP in 45 patients (51.1%) and Impella
5.0 in 8 patients (9.1%) and was not different between the pre- and post-PCI group. Eleven
patients (12.5%), were upgraded to a higher flow support device (Impella 5.0 or VA-ECMO),
not different between the pre-and post-PCI group. Median Impella support duration in survi-
vors was 84 hours in the pre-PCI group and 75 hours in the post-PCI group (p = 0.12).
Table 1. (Continued)
Pre-PCI Post-PCI
(n = 21) (n = 67) p
0 0 (0) 1 (1.5)
1 2 (9.5) 2 (3.0)
2 2 (9.5) 14 (20.9)
3 17 (81.0) 50 (74.6)
Intra-aortic balloon pump before Impella placement, n (%)� 0 (0) 12 (17.9) 0.03
Data are displayed as percentile (frequency), mean ± standard deviation or median [25th percentile - 75th percentile]. VF: ventricular fibrillation; VT: ventricular
tachycardia; PCI: percutaneous coronary intervention; CABG: coronary artery bypass grafting
� 6 patients received IABP prior to primary PCI and 6 patients after primary PCI but before Impella.
https://doi.org/10.1371/journal.pone.0235762.t001
Table 2. Clinical course of AMICS patients treated with primary PCI and Impella.
Pre-PCI Post-PCI
(n = 21) (n = 67) P
Mechanical circulatory support
Duration of Impella support
Duration of Impella support in survivors, (median, hours) � 84 [33–162] 75 [50–125] 0.84
Duration of Impella support in non-survivors, (median, hours) � 62 [15–230] 31 [6–62] 0.18
First Impella Device 0.87
Impella 2.5 8 (38.1) 27 (40.3)
Impella CP 11 (52.4) 34 (52.2)
Impella 5.0 2 (9.5) 6 (9.0)
Change of mechanical support device, n (%) 3 (14.3) 8 (11.9) 0.77
Upgrade to Impella 5.0 3 (14.3) 6 (9.0)
Upgrade to ECLS - 2 (3.0)
Device failure requiring extraction of the device, n (%) 1 (4.8) - 0.07
During admission
Inotropic or vasopressor therapy, n (%) 19 (90.5) 63 (94.0) 0.57
Renal replacement therapy, n (%) 9 (42.9) 26 (38.8) 0.74
Mechanical ventilation, n (%) 18 (85.7) 65 (97.0) 0.05
Peak CKMB, μmol/L 445 [141–1023] 454 [204–804] 0.28
Blood products, n (%) 13 (61.9) 38 (56.7) 0.67
Admission to the intensive care unit, n (%) 17 (85.0) 59 (89.4) 0.59
Days on the intensive care unit in survivors 8 [2–17.7] 13 [4–31] 0.16
Days on the intensive care unit in non-survivors 3 [0.5–10.5] 2.5 [1–4] 0.95
� Sum of support duration of all given support devices. PCI = percutaneous coronary intervention. ECLS = extra
corporeal life support.
https://doi.org/10.1371/journal.pone.0235762.t002
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Admission to the ICU was not statistically different between the pre- and post-PCI group
(85% versus 89.4%, p = 0.59). In the pre-PCI group, there was a trend towards less mechanical
ventilation (85.7% versus 97.0%, p = 0.051) and shorter hospitalization on the ICU (median of
8 versus 13 days, p = 0.16) in survivors.
Complications
There were no significant differences in the frequency of complications between the two
groups (Table 3). Two patients were diagnosed with stroke during admission (2.3%), both in
the post-PCI group. Device related vascular complications occurred in 14 patients (15.9%) and
occurred more often in the pre-PCI group (23.8% versus 13.4%, p = 0.25). Two patients (9.5%)
in the pre-PCI group had a major access site related bleeding versus 7 (10.4%) in the post-PCI
group. Four patients experienced limb ischemia requiring surgery (2 in both groups). Clini-
cally relevant hemolysis occurred in 9.1% of the patients, all in the post-PCI group. Non-device
related bleeding occurred in 13 patients (14.8%).
Outcome
The overall all-cause 30-day mortality was 58.0%, with 47.6% in the pre-PCI group versus
61.2% in the post-PCI group (HR 0.7, 95% CI 0.3–1.3, p = 0.21), Fig 1. The 30-day cardiac
Table 3. Clinical outcome of AMICS patients treated with primary PCI and Impella.
Pre-PCI Post-PCI
(n = 21) (n = 67) p
In-hospital outcome
Stroke, n (%) - 2 (3.0) 0.42
Hemorrhagic stroke - 1 (1.5)
Ischemic stroke - 1 (1.5)
Device related vascular complication, n (%) 5 (23.8) 9 (13.4) 0.25
Limb ischemia 2 (9.5) 2 (3.0)
Access site related bleeding 3 (14.3) 7 (10.4)
Major bleeding 2 (9.5) 7 (10.4)
Minor bleeding 1 (4.8) -
Access site infection
Non-device related bleeding 3 (14.3) 10 (14.9) 0.94
Gastro-intestinal bleeding 1 (4.8) 5 (7.5)
Other location 2 (9.5) 5 (7.5)
Clinically relevant hemolysis, n (%) - 8 (11.9)
Follow-up outcome
30-day all-cause mortality, n (%) 10 (47.6) 41 (61.2) 0.27
Cardiac mortality 4 (19.0) 30 (44.7) 0.03
Neurological mortality 3 (14.2) 7 (10.4) 0.69
Other reason 3 (14.2)� 4 (6.0)�� 0.20
1 year all-cause mortality, n (%) 11 (52.4) 43 (64.2) 0.33
� persisting respiratory insufficiency due to aspiration pneumonia in 1 patient and recurrent heart failure in 2
patients
�� haemorrhagic shock due to device related retroperitoneal bleeding in 1 patient, in-hospital cardiac arrest due to
obstructive shock/ lung embolism in 1 patient, sepsis and progressive metastases of underlying colon carcinoma in 1
patient and recurrent heart failure in 1 patient.
https://doi.org/10.1371/journal.pone.0235762.t003
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mortality was significantly reduced in the pre-PCI group, 19.0% versus 44.7% in the post-PCI
group (HR 0.3, 95% CI 0.09–0.96, p = 0.04), Fig 2. Neurological mortality did not differ signifi-
cantly between the pre-PCI and post-PCI group (respectively 14.2% versus 10.4%, HR 1.4, 95%
CI 0.3–6.1). After multivariable analysis, there was also no statistically significant difference in
Fig 1. Short term all-cause mortality in AMICS patients treated with primary PCI and pre- versus post-PCI Impella support.
https://doi.org/10.1371/journal.pone.0235762.g001
Fig 2. Short term cardiac mortality in AMICS patients treated with primary PCI and pre- versus post-PCI Impella support.
https://doi.org/10.1371/journal.pone.0235762.g002
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30-day all-cause mortality between the pre-PCI and post-PCI group (HR 0.8, 95% CI 0.4–1.6,
p = 0.50).
Discussion
This prospective single-center observational study in AMICS patients evaluated the potential
association between timing of Impella initiation and mortality. The key findings of our study
were that 1) 30-day all-cause mortality was still very high (58%) despite successful primary PCI
and mechanical circulatory support with Impella, 2) pre-PCI Impella initiation was not associ-
ated with a statistically significant difference in 30-day all-cause mortality, compared to post-
PCI Impella initiation, 3) pre-PCI Impella initiation was associated with a clinically and statis-
tically significant reduction in 30-day cardiac mortality compared to post-PCI Impella
initiation.
This study included a very high risk AMICS patient population with nearly 50% of patients
admitted after an out-of-hospital cardiac arrest, which in itself is associated with poor survival
[23, 24]. This study population was similar to populations in previous trials that assessed early
Impella initiation in AMICS patients [20–22, 25]. In these studies a significant mortality reduc-
tion was reported in patients who received Impella pre-PCI. Basir et al. performed a retrospec-
tive study in 287 patients [20]. Patient data was retrieved from the cVAD registry. However, in
their analysis, patients who received Impella till 24 hours post-PCI were also included, which
could have led to bias due to more profound CS in the group of patients with late Impella
implantation. In the present study only patients who received Impella in the admission proce-
dure, either pre- or post-PCI, were included. Moreover, important potential confounders that
differed significantly at baseline (i.e. unsuccessful PCI) were not included in their multivari-
able model and the exact number of patients who had Impella initiation before PCI was not
stated. Jensen et al. and Loehn et al. also reported a beneficial effect of early Impella initiation,
although both studies had a small sample size [21, 22]. In the study by Loehn et al, all patients
were treated with the Impella CP, which provides more hemodynamic support than the
Impella 2.5. In our study, 40% of patients were treated with the Impella 2.5, which was equal
between the pre-PCI and post-PCI group.
Neurological mortality did not differ significantly between the pre- and post-PCI group.
This finding stresses out the necessity to be able to accurately predict which patients will
recover from coma in the acute phase and which patients will not. Part of admitted patients
after out-of-hospital cardiac arrest will not recover from coma, no matter the effort. Probably,
(early) restoration of hemodynamics will not be beneficial in this subgroup of patients. How-
ever, till date it is impossible to accurately predict which patients will recover from coma after
AMICS or cardiac arrest and which patients will not.
Interestingly, in our analysis, cardiac mortality was significantly lower in the pre-PCI
group. Till date, no clinical studies with hemodynamic support devices have extended the ben-
efit of primary PCI in AMI or AMICS yet. Especially in CS it is postulated that stabilizing the
systemic circulation with a hemodynamic support device could reduce mortality, as longer
duration of CS, with subsequently the occurrence of multi-organ failure and systemic inflam-
matory response syndrome (SIRS) is associated with higher mortality [26, 27]. Early implanta-
tion of a hemodynamic support device, i.e. pre-PCI, could be of importance, since multiple
pre-clinical studies showed a beneficial effect on infarct size by unloading the left ventricle and
lowering myocardial oxygen demand [28–30]. The question remains however, whether the
possible benefits of pre-PCI hemodynamic support, i.e. with a direct LV unloading device as
Impella, justify a longer time to restoration of flow in the culprit artery [31]. In a recent clinical
pilot study (n = 50) by Kapur et al, it was shown for the first time that pre-PCI initiation of
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Impella CP was not associated with larger infarct size despite an average of 30 minutes longer
ischemic time [32]. However, reduction of infarct size with a pre-PCI strategy, still needs to be
confirmed in the setting of AMICS.
While our study showed a significantly reduced 30 day cardiac mortality in the pre-PCI
group, the 30 day all-cause mortality did not differ significantly. Our findings stress out the
need for confirming data from an adequately powered RCT. The results of the DanGer Shock
trial, which randomizes AMICS patients between Impella CP prior to PCI and current guide-
line driven therapy, are therefore eagerly awaited [33].
Limitations
There are several limitations that apply to this analysis. This analysis is a single center study
with an observational design. The sample size is relatively small. Moreover, timing of Impella
initiation was not dictated per protocol which may have led to selection bias. It remained
unclear what the reason for pre-PCI Impella initiation was. Therefore, potential unmeasured
confounding bias cannot be ruled out. We performed multivariable analysis, but this was lim-
ited due to the small sample size of our cohort. Finally, there are several factors that might
have influenced the results, such as experience with the device, change of therapy over time,
improvement of general therapy of AMICS patients over time, and change in patient selection
over time. Given the abovementioned limitations, the findings of our study should be inter-
preted as hypothesis generating.
Conclusion
Despite early revascularization and Impella support, 30-day mortality was still very high in
patients with AMICS. Pre-PCI Impella initiation in AMICS patients was not associated with a
statistically significant difference in 30-day all-cause mortality, compared to post-PCI Impella
initiation. Future large randomized clinical trials will be needed to assess whether pre- or post-







Conceptualization: Krischan D. Sjauw, Dagmar M. Ouweneel, José P. S. Henriques.
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